Exchange: OTC·Updated 11:45 AM EDT

BIXT Bioxytran Inc

$0.0226
$0.0008
(3.42%)
Today
Mkt Cap$2.59M
Vol22,000.00

About BIXT

BioXyTran, Inc. engages in the development, manufacture, and commercialization of therapeutic drugs designed to address hypoxia in humans, which is a lack of oxygen in tissues. Its product pipeline includes BXT-25, a drug designed to oxygenate ischemic (reduced blood flow) regions in the brain that suffered from hypoxia during a brain stroke, and BXT-252, which treats chronic wounds resulting from ischemia caused by occlusion of capillaries. The company was founded on June 9, 2008 and is headquartered in Needham, MA.
47

Neutral Sentiment

How do you feel about BIXT?

Advertisement|Remove ads.